PRECLINICAL WHITE PAPERS & ARTICLES

  • A Structured Approach To Enhancing Bioavailability For Early Development Phase Molecules
    A Structured Approach To Enhancing Bioavailability For Early Development Phase Molecules

    The extensive timeline to develop a drug is due to a multitude of formulation challenges that formulation experts face. When it comes to solving these challenges, there have been significant advancements in drug development techniques to counter these challenges including bioavailability, stability, efficacy, manufacturability, and safety.

  • Understanding The Power Of Natural Killer Cells And New Nonradioactive Assay Approaches
    Understanding The Power Of Natural Killer Cells And New Nonradioactive Assay Approaches

    With proactive planning and validated processes, NK cell functional analysis can support a range of various immunotoxicity endpoints in a study, from discovery and development to the clinic.

  • Phase I Studies: From First Drug Design To First-In-Human Studies
    Phase I Studies: From First Drug Design To First-In-Human Studies

    Phase I is often seen as the gateway between scientific research and clinical medicine, and the outcome of the trials have a major impact on the next steps of any prospective drug.

  • Precision Medicine In Immuno-Oncology
    Precision Medicine In Immuno-Oncology

    The ongoing advances in cancer immunotherapy together with precision medicine may promise a bright future for patients. Learn about the two most common biomarkers in clinical trials that are critical for the drug development process.

  • What Does The Chan Zuckerberg Biohub Mean For Clinical Research And EDC?
    What Does The Chan Zuckerberg Biohub Mean For Clinical Research And EDC?

    Medical research has seen a great deal of high-profile philanthropic investment in recent years. Last year, for example, tech billionaire Sean Parker made a $250 million donation to further the development of immunotherapy. More recently, the Chan Zuckerberg Biohub has made headlines by announcing plans to invest $3 billion in new research over the next 10 years. The investment is part of the Biohub’s ambitious goal of curing all disease by the end of the century. It will be directed toward a wide array of medical solutions including new drugs, vaccines, and diagnostic tests - and the first round of grant recipients has already been chosen.

More White Papers & Articles

PRECLINICAL APPLICATIONS & STUDIES

More Applications & Studies

PRECLINICAL SOLUTIONS

More Solutions

PRECLINICAL SUPPLIERS

  • PRA Health Sciences
    PRA Health Sciences

    PRA is a global Clinical Research Organization providing services through all phases of clinical development. PRA has supported over 3,100 clinical trials in more than 80 countries on 6 continents through our global offices. PRA's therapeutic expertise, global reach, and project experience with local knowledge enable our project teams to deliver consistent and on time performance for our clients.

  • MPI Research
    MPI Research

    MPI Research, with global headquarters in Mattawan, Michigan, provides discovery, safety evaluation, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries.

More Suppliers